



## Arvinas to Present at 41st Annual J.P. Morgan Healthcare Conference

January 4, 2023

NEW HAVEN, Conn., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Houston, Ph.D., President and Chief Executive Officer of Arvinas, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 1:30 p.m. PT in San Francisco, Calif.

A live audio webcast of the presentation will be available [here](#) and on the Events & Presentations section of the Investors & Media section of the Company's website.

### About Arvinas

Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC<sup>®</sup> Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC<sup>®</sup> targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC<sup>®</sup> protein degraders against validated and "undruggable" targets, the company has three investigational clinical-stage programs: bavdegalutamide (ARV-110) and ARV-766 for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit [www.arvinas.com](http://www.arvinas.com).

### Contacts

#### Investors:

Jeff Boyle  
+1 (347) 247-5089  
[Jeff.Boyle@arvinas.com](mailto:Jeff.Boyle@arvinas.com)

#### Media:

Kirsten Owens  
+1 (203) 584-0307  
[Kirsten.Owens@arvinas.com](mailto:Kirsten.Owens@arvinas.com)